Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.
Oncology, Medical March 11th 2024
Renal & Urology News
This study illuminates the potential of preoperative circulating tumor DNA to redefine the approach to treating high-risk upper tract urothelial carcinoma, offering a nuanced tool for assessing the necessity of neoadjuvant chemotherapy and tailoring patient care.
Oncology, Medical March 4th 2024
Clinical Advances in Hematology & Oncology
ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.
Oncology, Medical January 16th 2024
Clinical Oncology News
The future of advanced bladder cancer treatment has been crystallized by the findings of the EV302 study, which demonstrated a median overall survival of 31.5 months with enfortumab vedotin-ejfv plus pembrolizumab.
Oncology, Medical November 13th 2023
A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.
Cancer Therapy Advisor
The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.
Oncology, Medical November 6th 2023